• A major contributor to the understanding of molecular mechanism of EGFR mutation-conferred
drug resistance in non-small-cell lung cancer
• A major contributor to the invention of the first third-generation high-selectivity and low-
toxicity candidate compound WZ4002 to overcome EGFR T790M drug resistance
• A major contributor to the invention of the first fourth-generation allosteric inhibitor EAI045 to
overcome EGFR L858R/T790M/C797S drug resistance
• Author and co-author over 50 articles in Nature, Cell and other leading journals
• Head of the Drug Discovery Platform, National Research Center for
Translational Medicine, Shanghai Jiao Tong University
• Previously A Research Scientist at Dana-Farber Cancer Institute, Boston
• Previously A Principle Assistant Investigator at Massachusetts General
Hospital, Boston
• A leading contributor to the first generation BCR/ABL allosteric inhibitor - the prototype of
Asciminib developed and launched by Novartis
• More than 80 research articles in Nature and other leading journals
• Inventor of multiple international patents
Caihong Yun, Ph.D. | Co-founder
Co-Founder, Vice President
Mr. Xin Huang received his bachelor’s and master’s degrees from the School of Medicines, Peking University. From 2007 to 2018, he served in the New Drug Research, Marketing, Group President Office and Investment & Development at Sincere Pharmaceutical Group. He has led the research and development of many innovative drugs including Edaravone. He was also responsible for the successful launch of Bi Cun (Edaravone Injection) in China. Major achievements included completion of the 2013 commercial partnership of Sincere and Bristol-Myers Squibb on Orencia® in China, among several other major research collaboration and partnership.
|
|
Nanjing ｜307-311, Building No.9, 669-8 Xuanwu Avenue, Xuanwu District Shanghai｜Suite 901, 880 Xiangyang Road, Minhang District Beijing ｜Suite 205, Building No.2, PKUCare Industrial Park, Changping District Website: https://www.redcloudbio.com